| Ambrx Biopharma Inc. |
10%+ Owner |
Ordinary Shares |
35,700,000 |
$381,022,530 |
$10.67 |
23 Feb 2023 |
By Commodore Capital Master LP |
| Vera Therapeutics, Inc. |
10%+ Owner |
Class A Common Stock |
4,400,000 |
$79,200,000 |
$18.00 |
10 Jan 2024 |
By Commodore Capital Master LP |
| Enliven Therapeutics, Inc. |
10%+ Owner |
Common stock, par value $0.001 per share |
1,448,640 |
$21,925,166 |
$15.14 |
23 Feb 2023 |
By Commodore Capital Master LP |
| Vistagen Therapeutics, Inc. |
10%+ Owner |
Common Stock |
1,575,000 |
$2,704,275 |
$1.72 |
07 Aug 2023 |
By Commodore Capital Master LP |
| Satsuma Pharmaceuticals, Inc. |
10%+ Owner |
Common Stock, par value $0.0001 per share |
461,286 |
$325,668 |
$0.7060 |
14 Nov 2022 |
By Commodore Capital Master LP |
| Vistagen Therapeutics, Inc. |
10%+ Owner |
Pre-Funded Warrants (Right to Buy) |
2,788,620 |
|
|
04 Oct 2023 |
By Commodore Capital Master LP |
| Vistagen Therapeutics, Inc. |
10%+ Owner |
Tranche 2 Warrants (Right to Buy) |
1,690,014 |
|
|
04 Oct 2023 |
By Commodore Capital Master LP |
| Vistagen Therapeutics, Inc. |
10%+ Owner |
Tranche 1 Warrants (Right to Buy) |
1,394,310 |
|
|
04 Oct 2023 |
By Commodore Capital Master LP |